Trial Profile
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Mipasetamab uzoptirine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ADC Therapeutics
- 30 Mar 2020 Status changed from suspended to discontinued.
- 09 Jan 2020 Status changed from recruiting to suspended.
- 16 Jan 2019 According to an ADC Therapeutics media release, the first patient has been dosed in this study.